Uscom Limited (UCM) AI Stock Analysis

• Market Cap: AU$3.12M
• Dividend Yield: N/A
• Average Volume (3M): 3.23K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.90
• Revenue Growth: -30.80%
• EPS Growth: -38.95%
• Country: AU
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 260,147,130
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 3,233
• PEG Ratio: -0.02
• Price to Book (P/B): -76.24
• Price to Sales (P/S): 1.13
• P/FCF Ratio: -1.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: AU$0.01 ▲(10.00% Upside)

Uscom Limited's overall stock score is primarily impacted by its weak financial performance and unfavorable valuation metrics. The company's financial instability, characterized by declining revenues and negative equity, is a significant concern. Additionally, technical analysis indicates bearish momentum, further contributing to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Product Offering

Uscom's focus on innovative non-invasive monitoring devices, like the Uscom 1A, positions it well in the growing healthcare technology sector, providing a competitive edge in improving patient outcomes.

Recurring Revenue

The company's strategy of generating recurring revenue through service contracts and training provides a stable income stream, enhancing financial predictability and customer retention.

Operational Efficiency

A high gross profit margin indicates strong operational efficiency, suggesting that the company can maintain profitability on its core products despite overall financial challenges.

Negative Factors

Financial Instability

The negative equity and poor debt-to-equity ratio highlight potential solvency issues, which could limit the company's ability to invest in growth and innovation.

Revenue Decline

A significant decline in revenue growth indicates challenges in market demand or competitive pressures, potentially impacting long-term sustainability and market position.

Cash Flow Challenges

Negative operating cash flow suggests that the company struggles to generate sufficient cash from operations, which could hinder its ability to fund ongoing operations and strategic initiatives.

Uscom Limited Business Overview & Revenue Model

Company Description

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company also provides the SpiroSonic AIR, a digital multipath ultrasonic spirometer with a viral disinfection system for the elimination of COVID and tuberculosis; and respiratory devices. It serves hospitals and other medical care locations through a network of distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

How the Company Makes Money

Uscom generates revenue through the sale of its medical devices, primarily the Uscom 1A, to hospitals, clinics, and healthcare providers. The company also benefits from recurring revenue generated through service contracts, maintenance agreements, and training for healthcare professionals. Additionally, Uscom may engage in partnerships and collaborations with other medical technology firms and healthcare organizations to enhance its product offerings and expand its market reach, contributing to its overall earnings.

Uscom Limited Financial Statement Overview

Summary

Uscom Limited is facing significant financial challenges. The income statement shows a substantial decline in revenue and ongoing losses, with negative net profit and EBIT margins. The balance sheet reveals financial instability with negative stockholders' equity and a highly unfavorable debt-to-equity ratio. Although there is some improvement in free cash flow, overall financial health is concerning due to high leverage and insufficient profitability.

Income Statement

Uscom Limited's income statement reveals significant challenges. The company has experienced a substantial decline in revenue, with a negative revenue growth rate of -28.98% in the most recent year. Profitability metrics are concerning, with negative net profit and EBIT margins, indicating ongoing losses. The gross profit margin remains high at 86.48%, suggesting some operational efficiency, but overall financial performance is weak due to persistent losses.

Balance Sheet

The balance sheet of Uscom Limited shows financial instability. The company has a negative stockholders' equity, leading to a highly unfavorable debt-to-equity ratio of -59.22. This indicates potential solvency issues. Return on equity is alarmingly high at 86.41%, driven by negative equity, which is not sustainable. The equity ratio is also negative, reflecting a precarious financial position.

Cash Flow

Cash flow analysis for Uscom Limited indicates some improvement in free cash flow growth, which is positive at 79.47%. However, operating cash flow remains negative, and the operating cash flow to net income ratio is below 1, suggesting insufficient cash generation to cover losses. The free cash flow to net income ratio is slightly above 1, indicating some ability to manage cash flow despite ongoing losses.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.58M	2.58M	3.73M	2.66M	2.51M	3.86M
Gross Profit	2.23M	2.23M	3.12M	-1.03M	-1.21M	781.70K
EBITDA	-3.06M	-3.06M	-1.51M	-2.50M	-1.84M	-833.84K
Net Income	-3.30M	-3.30M	-2.07M	-2.59M	-1.97M	-924.24K
Balance Sheet
Total Assets	3.25M	3.25M	5.13M	5.18M	7.99M	5.33M
Cash, Cash Equivalents and Short-Term Investments	966.66K	966.66K	2.52M	2.18M	4.70M	1.71M
Total Debt	2.26M	2.26M	989.28K	1.09M	1.31M	1.43M
Total Liabilities	3.29M	3.29M	2.07M	2.14M	2.06M	2.26M
Stockholders Equity	-38.22K	-38.22K	3.06M	3.04M	5.94M	3.08M
Cash Flow
Free Cash Flow	-2.72M	-2.72M	-1.22M	-1.58M	-1.08M	21.63K
Operating Cash Flow	-2.71M	-2.71M	-1.16M	-1.42M	-967.51K	54.98K
Investing Cash Flow	-68.78K	-68.78K	-57.55K	-151.94K	-115.31K	-33.35K
Financing Cash Flow	1.21M	1.21M	1.57M	-952.96K	4.05M	-281.87K

Uscom Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Neutral
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, equal to the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 9.10 is Positive, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.

Uscom Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CBL	51 Neutral	AU$25.54M	-2.66	-103.74%	―	14.84%	39.64%
AT1	48 Neutral	AU$30.79M	-4.94	-58.27%	―	-7.20%	28.70%
HMD	43 Neutral	AU$46.02M	-8.27	-513.22%	―	-34.06%	75.47%
IRX	42 Neutral	AU$6.16M	-4.03	―	―	―	-55.00%
UCM	39 Underperform	AU$3.12M	-0.91	-218.52%	―	-30.80%	-38.95%
ADR	37 Underperform	AU$18.55M	-0.64	-1476.79%	―	-2.82%	32.47%

Uscom Limited Corporate Events

Uscom Limited Announces FY2025 Results and Strategic Plans for FY2026

Uscom Limited, a leader in medical technology, has announced its FY2025 results and outlined drivers for FY2026. The company has achieved significant milestones, including global clinical adoption and sales in 52 countries, supported by over 1,200 peer-reviewed publications. Uscom’s strategic partnership with Foxconn for manufacturing and global distribution is expected to enhance its market position, focusing on high-margin products and expanding its digital and wireless technology offerings.

The most recent analyst rating on (AU:UCM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Uscom Limited stock, see the AU:UCM Stock Forecast page.

Uscom Limited Approves Disposal of Main Undertaking

Uscom Limited has announced the results of a recent meeting where a resolution was passed to approve the disposal of the company’s main undertaking. The resolution was decided by a poll, with 59.86% voting in favor and 40.14% voting against, indicating a significant decision that could impact the company’s future operations and strategic direction.

Uscom Limited Announces Asset Sale Amid Financial Challenges

Uscom Limited is facing a challenging financial situation, exacerbated by global events such as COVID-19, geopolitical tensions, and trade wars, which have significantly impacted its revenue and led to consecutive years of losses. The company has decided to sell its assets to clear debts and provide a path forward for creditors, while shareholders will retain their interest in the ASX-listed entity. This strategic move aims to ensure the continuation of Uscom’s life-saving technologies and potentially leverage its tax losses for future business opportunities.

Uscom Limited Faces Q1 Challenges Amid Global Economic Uncertainty

Uscom Limited reported a challenging first quarter with a decrease in customer receipts and cash on hand, attributed to global economic uncertainties such as US tariff wars and shifts in European public spending. Despite these challenges, the company remains optimistic about the long-term value of its cardiovascular and pulmonary technologies, which address major health issues. Uscom continues to focus on compliance with global regulatory demands while anticipating a normalization of commercial environments to support its growth.

Uscom Limited Announces Digital-First Annual General Meeting

Uscom Limited has announced its Annual General Meeting of Shareholders, scheduled for November 27, 2025, in Sydney. The company will not send physical copies of the meeting notice, opting instead for electronic distribution. Shareholders are encouraged to participate and vote on resolutions, either in person or via proxy forms, which must be submitted by November 25, 2025. This approach underscores Uscom’s commitment to digital engagement and efficient shareholder communication.

Uscom Limited Announces 2025 AGM and Key Resolutions

Uscom Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney. Key agenda items include the consideration of the company’s financial report for the year ending June 30, 2025, the adoption of the remuneration report, and the re-election of Mr. Brett Crowley as a director. The remuneration report, which outlines the company’s policies on director and executive compensation, will be presented for an advisory vote. The re-election of Mr. Crowley, an independent non-executive director, is recommended by the board. These resolutions reflect Uscom’s commitment to transparency and governance, potentially impacting shareholder confidence and the company’s strategic direction.